Eli Lilly and Co. plans to open a new Lilly Gateway Labs site in Philadelphia. The new Gateway Labs site will occupy 44,000 sq.-ft. of 2300 Market, a life sciences facility in Center City newly developed and operated by Breakthrough Properties. Biotechs based in the site will have access to dedicated, fully equipped wet lab facilities alongside the strategic scientific engagement associated with the Gateway Labs approach.  

“Philadelphia has long led biotech innovation, from early vaccine development to pioneering gene therapy and CAR-T treatments and discovering new approaches to Alzheimer’s disease. Today’s local biotech scene builds on that legacy with founders tackling medicine’s toughest challenges,” said Julie Gilmore, Ph.D., vice president, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management. 

With the addition of Philadelphia, Gateway’s U.S. footprint now includes four centers, including Boston, South San Francisco, and San Diego. In each location, Lilly Gateway Labs supports community-building across life science sectors, supporting biotech efforts, venture partners, and other partners.

Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which support biotechs by providing access to strategic capital, lab space and technology, and R&D capabilities including AI models. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than $3 billion, supporting more than 50 therapeutic programs.